Lilly signs licensing deal with Mediar for IPF drug

Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar’s drug MTX-463 into Phase 2 testing for idiopathic pulmonary fibrosis.

Mediar said it expects to initiate a Phase 2 study in the first half of